Skip to main content

Treatment Clinical Trials for Non-Small Cell Lung Cancer

Review the non-small cell lung cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 276-300 of 425

SX-682 with Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Durvalumab for the Treatment of Patients with Stage IA2-III Non-small Cell Lung Cancer who Have Minimal Residual Disease
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Neoadjuvant Trastuzumab Deruxtecan for the Treatment of Stage II, IIIA, IIIB HER2-Amplified or HER2-Mutated Non-small Cell Lung Cancer, HERCULES Trial
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Stereotactic Body Radiation Therapy Planning with Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
Status: Active
Location: Northwestern University, Chicago, Illinois
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Circulating Tumor DNA Monitoring for Treatment Response Prediction and Treatment Reduction after Surgery in Patients with Stage IB, II, and IIIB Non-small Cell Lung Cancer, DNA-PREDICT Trial
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Responder-derived Fecal Matter Transplant and Pembrolizumab for the Treatment of Relapsed/Refractory PD-L1 Positive Non-small Cell Lung Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Dual Immune Strategy (Nivolumab and Ipilimumab) versus Single Checkpoint Blockade (Pembrolizumab) in Combination with Chemotherapy for the Treatment of PD-L1 Negative Stage IV Non-small Cell Lung Cancer, DISCERN Trial
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
GT103 in Combination with Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Status: Active
Location: 3 locations
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Lorlatinib plus Local Consolidation Therapy for the Treatment of ALK Positive Stage IV Non-small Cell Lung Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
SAR445877 for the Treatment of Locally Advanced or Metastatic ICI-Refractory Non-Small Cell Lung Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
DRP-104 for the Treatment of NFE2L2- or KEAP1-altered Advanced, Recurrent, Metastatic, and/or Unresectable Non-small Cell Lung Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tiragolumab with Carboplatin, Pemetrexed, and Atezolizumab for the Treatment of Non-squamous Non-small Cell Lung Cancer and Untreated Brain Metastases
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Fingolimod for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Biomarkers for Predicting Response to SAR444881 in Combination with Cemiplimab in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, or Ovarian Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland